Mira is a principal at 5AM Ventures, an early-stage life sciences venture firm with offices in Menlo Park, CA and Boston, MA. In this role, she performs scientific and company due diligence on new investment opportunities and supports portfolio companies as a board observer.
Mira has a particular interest in early-stage therapeutics companies as well as life science research technologies. She is a board observer for Precision Nanosystems, Chrono Therapeutics, and Purigen Biosystems. Precision Nanosystems has developed a manufacturing technology for lipid and polymer nanoparticles, providing tools for nanomedicine drug development and cell-specific delivery to study, diagnose, and treat disease. Chrono Therapeutics is developing a new nicotine delivery technology for smoking cessation that is currently in clinical trials. Purigen leverages a new implementation of a classical analytical chemistry process to purify high quality nucleic acids from complex clinical and research samples.
Mira is also an advisor to the Bay Area Biotech Consulting group, a nonprofit that matches life science graduate students and postdoctoral fellows with startup companies for short-term consulting projects. These opportunities give students exposure to industry and give startups access to scientific experts whose insights inform scientific, business development, and sales and marketing strategies.
Education, Personal, and Fellowship
Mira holds a BA in biology from Carleton College and a PhD in biological sciences from the University of California, San Diego and The Salk Institute for Biological Studies, where she studied infectious diseases. Mira completed her postdoctoral training at Genentech in cancer biology.
Under the mentorship of Managing Partner Kush Parmar (Class 16), Mira served her fellowship at 5AM Ventures in Boston, MA. She is a member of Class 21.